This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
More than a decade after earning FDA approval for Xiaflex as a nonsurgical treat...
More than a decade after earning FDA approval for Xiaflex as a nonsurgical treat...
Arnie told us he’d be back. Three months after becoming Zimmer Biomet’s chief mo...
The government price negotiations affecting Keytruda wouldn't take effect until ...
Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-qu...
Following an inspection of Piramal’s production facility in Maharashtra, India, ...
At a press conference in Washington, D.C. dubbed “Lilly in America,” the Indiana...
At a press conference in Washington, D.C. dubbed “Lilly in America,” the Indiana...
Blood test maker Grail has recruited ‘Grey’s Anatomy’ star Kate Walsh to join a ...
The company is adding higher-dose Zepbound options to its online pharmacy and tr...
Compounding pharmacies aren’t surrendering their ability to create cheaper knock...
Blood test maker Grail has recruited ‘Grey’s Anatomy’ star Kate Walsh to join a ...
On the heels of a move to reduce its viral vector manufacturing workforce, Therm...
As Stelara biosimilars gradually make their way on to the U.S. market, Johnson &...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
HHS secretary Robert F. Kennedy Jr. has been on the receiving end of two heated ...
Granules shelled out a reported 20 million Swiss francs ($22.3 million) to acqui...
Looking to avoid a repeat of the shortages that plagued Mounjaro and Zepbound du...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
Revenues in the biopharma industry continued to boom in the fourth quarter of la...
Revenues in the biopharma industry continued to boom in the fourth quarter of la...
Hear from UCB’s Brad Chapman on the importance of inclusion, representation, and...
A little less than two years after San Francisco’s Mirum Pharmaceuticals ponied ...
A new awareness campaign from Abbott highlights a major sticking point in diabet...